drugset / Trial / NCT01631097
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NaSingle-groupOpen-labelBasic science
Summary
This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics, safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of hepatic impairment and normal hepatic function.
Timeline
- Start
- 2012-05
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivozanib | Small molecule | 1.5 mg | Oral |
Indications
No indication recorded.